Response to hepatitis B virus (HBV) infection [HBV surface antigen (HBsAg) 
HBs(+) Also, those who are HBsAg(+) have significantly higher percent iron saturation (serum iron/total iron mdig capacity). That is, the hypothesis was supported by the findings. Several additional biological hypotheses are suggested, including a possible role of increased iron levels in susceptibility and response to HBV infection and the possible relationship between higher iron levels and the likelihood of HBV infection progressing to primary hepatocellular carcinoma. In addition, further tests of the initial hypothesis in nonhospitalized populations with endemic HBV infection are proposed.
The role of iron in susceptibility and response to infectious disease (primarily bacterial but possibly viral) has been discussed for some years and has recently been summarized (1) . Serum iron becomes elevated in hepatitis, presumably released from hepatocytes as a result of cellular damage. We found that males with Down syndrome who had hepatitis B surface antigen (HBsAg) in their blood had significantly higher levels of serum iron than those who did not have HBsAg (2) . However, the serum iron level was not correlated with the level of serum glutamic pyruvic transaminase (SGPT) (aspartate aminotransferase; L-aspartate:2-oxoglutarate aminotransferase, EC 2.6.1.1), which is considered to be an indication of liver cell damage. Therefore, it appeared that the higher serum iron in the HBsAg(+) (HBsAg positive) individuals was not due only to the release of cellular iron which accompanies liver damage. Based on these observations, we decided to study a second group of individuals at high risk of hepatitis B virus (HBV) infection. Specifically, we tested the hypothesis that the serum iron level is higher in patients on chronic renal dialysis who have HBsAg in their blood than those who have antibody to HBsAg (antiHBs) or those who lack both HBsAg and anti-HBs (no evidence of infection).
There are additional reasons for learning more about the relationship of iron to hepatitis infection. Tumor cells may require iron for effective growth and spread (3) . Infection with HBV is significantly associated with chronic liver disease and primary cancer of the liver in Asia, Africa, and other regions where these are common diseases. The relation may be etiologic, and we are currently studying strategies for the control of HBV infection. In connection with this, it is important to identify interactions that might contribute to the development of cancer. In the tropics, iron metabolism in humans is affected by a large number of environmental and pathologic conditions, including nutrition, methods of food preparation, hemolytic anemias, and bacterial and viral infection (3, 4) . Further study of iron in relation to hepatitis B infection may contribute to an understanding of this complex problem.
METHODS
Sera were collected in iron-free tubes over a 4-day period from patients in two commercial renal dialysis clinics operated by Biomedical Applications of Philadelphia. Serum iron, total iron-binding capacity, SGPT, HBsAg, and anti-HBs were determined at The Institute for Cancer Research. Serum iron and total iron-binding capacity were determined colorimetrically with Hyland Ferro-chek II kits (Travenol, Costa Mesa, CA), HBsAg by the Ausria II method (Abbott), and anti-HBs by direct hemagglutination with HBsAg-coated erythrocytes (Electronucleonics Laboratories, Bethesda, MD) (5). Sera were considered positive for anti-HBs if they agglutinated cells at a titer of 1/4 or greater. SGPT was determined by a modification of the method of Henry et al. (6) . All other laboratory tests were performed by the commercial laboratory (Metpath, Philadelphia, PA) that routinely provides services for the dialysis clinic.
PATIENT POPULATION A total of 201 sera were collected. The distribution of patients by HBV response and sex is shown in Table 1 We then proceeded to search for interactions between the four variables: serum iron, sex, HBV response, and SGPT level. Iron levels were scored as low, middle, or high based on a division of the data into three groups containing approximately equal numbers of individuals. The distribution of the data according to these four variables is shown in Table 3 .
The testing of a series of hypotheses indicated that the data could be explained by considering only two-factor interactions.
(Details of this analysis are given in the Appendix.) Pairwise Three of the individuals from Table 1 had incomplete results and are not included.
interactions of these four variables were then evaluated to see how much each contributed to the explanation of the data. The best model consisted of the iron and HBV, iron and SGPT, HBV and SGPT, and sex and HBV interactions.
To determine whether any of these interactions were due to the effect of transfusions and intravenous iron therapy received by some patients, we removed all data from patients receiving either treatment within 1 month prior to iron and HBV testing and reanalyzed the remaining data. HBV response, SGPT level, and serum iron were considered, but not sex due to insufficient numbers. The interactions between iron and HBV and between iron and SGPT remained significant, while the interaction between HBV and SGPT was only marginally significant. The best model included the interactions between iron and SGPT and between iron and HBV and not the interaction between HBV and SGPT.
The interactions included in these models are consistent with previous observations. London and Drew (7) have shown that, in renal dialysis patients (which include the subjects of this study), males are significantly more likely to become carriers of HBsAg and females to develop anti-HBs. The virus and SGPT interaction has been known for many years (see for example, ref. 8) and was one of the criteria for the establishment of the association between Australia antigen and hepatitis. An increase of serum iron in association with liver damage (i.e., elevation of SGPT) has been clinically recognized in patients with hepatitis and liver disease. The interaction between iron and HBV was shown in the Down syndrome study and confirmed in this study. However, it was not recognized until this analysis that all four interactions act independently and simultaneously and, in particular, that the presence of HBsAg by itself, independent of SGPT elevation, is associated with elevations of serum iron. Implications This study indicates that the association of elevated serum iron with the presence of HBsAg in the serum is due not only to the breakdown of hepatic cells, but also to the presence of HBsAg itself. It is remarkable that these differences can be detected in this patient population given the possible masking effects of iron therapy, the anemia of chronic dialysis, and the decrease of iron absorption due to the use of aluminum hydroxide (9) .
We now wish to determine if these same associations exist in other populations with a high frequency of HBV infection-for example, nonhospitalized individuals in Africa, Asia, or Oceania. If our findings are supported in these populations, then there are some interesting biological and pathological questions that can be raised. All living cells require iron. In humans, a method of defense after microbial infection is to decrease the available iron by decreasing intestinal absorption and increasing liver storage. Do HBsAg carriers have a different response when faced with this stress? Are the increased iron levels a consequence of the HBV infection, or are individuals with high iron levels (or a propensity to develop them) more likely to become (11) have identified a glycoprotein present in various animal sera that can bind to HBsAg and prevent reaction with anti-HBs. Could the bacteria or glycoprotein contribute to increased levels of iron by preventing the recognition of HBsAg by the immune system? Millman et al. (12) have reported that transferrin is one of the host proteins associated with HBsAg. Transferrin saturated with iron (as opposed to unsaturated transferrin) is selectively bound to liver cells (13) . The transferrin is incorporated (by pinocytosis), and iron is released into the cell. Iron-laden transferrin on the surface antigen of HBV may facilitate the entry of the virus into the hepatocyte. It would be interesting to know if iron is detectable in appreciable amounts in purified HBsAg. Perhaps HBV interacts with normal erythropoietic mechanisms to alter utilization of iron. If there are additional stores of iron in HBsAg carriers, does that enhance their propensity to develop or foster the growth of primary hepatocellular carcinoma, and, if so, could this information be useful in prevention or treatment of this disease?
